IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene KLK10 Ensembl ENSG00000129451 Chromosome 19 Start 56207813 End 56215243
Description Kallikrein-10 Precursor (EC 3.4.21.-)(Protease serine-like 1)(Normal epithelial cell-specific 1) [Source:UniProtKB/Swiss-Prot;Acc:O43240]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 6358
     Entrez Gene : 5655
     UCSC : uc002pva.2
     GeneCards : 6358
     RefSeq : NM_001077500
     CCDS : CCDS12817.1
     Uniprot : O43240
     Interpro : O43240
     OMIM : 602673
     GeneTests : KLK10
     CGAP : KLK10
     PMID : 8764136

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  36838_at  -0.72  1.31e-2  2.95e-2  -0.09  8.16e-1  8.69e-1
 HG_U133A  209792_s_at  -1.38  5.28e-9  1.72e-8  -1.05  4.62e-11  5.89e-11
 HG_U133A  215808_at  -0.34  4.35e-7  1.17e-6  -2.35  2.10e-80  8.59e-80
 HG_U133_Plus2  209792_s_at  -1.16  2.24e-4  6.65e-4  -0.40  2.92e-1  3.51e-1
 HG_U133_Plus2  215808_at  0.36  8.89e-2  1.39e-1  1.28  9.87e-6  2.53e-5
 Stanford  9300  -1.83  1.91e-2  9.76e-2  0.20  7.72e-1  8.92e-1
 Agilent_HS_21.6K  1161  -0.55  2.90e-3  1.79e-2  -0.10  5.84e-1  7.18e-1

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  209792_s_at  0.58  3.95e-1  8.97e-1  -0.44  5.30e-1  1.00e+0
 HG_U133A  215808_at  -0.03  9.21e-1  9.95e-1  -0.47  1.98e-2  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 36838_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 209792_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 215808_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 209792_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 215808_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Stanford - 9300    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 1161    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
klk10 pancreatic cancer At least two kallikreins, KLK6 and KLK10, are significantly up-regulated in pancreatic cancer. 15015574 Human
klk10 pancreatic cancer DDD data showed a 13-fold increase in KLK10 expression in pancreatic cancer. 15015574 Human
klk10 ovarian cancers Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. 11920956 Human
kallikrein 10 ovarian cancers Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. 11920956 Human
klk10 cancer Recently, it has been reported that KLK10 is a tumor suppressor gene and that its expression is downregulated in various forms of cancer and cancer cell lines. 11920956 Human
klk10 tumor Recently, it has been reported that KLK10 is a tumor suppressor gene and that its expression is downregulated in various forms of cancer and cancer cell lines. 11920956 Human
klk10 ovarian cancer KLK10 is also upregulated in ovarian cancer. 11920956 Human
klk10 cancers We thus hypothesized that the KLK10 gene may be a target for mutations in various cancers. 11920956 Human
klk10 tumors METHODS: We sequenced the five coding exons of the KLK10 gene using genomic DNA from various tumors, normal tissues, and blood, by PCR amplification and automated sequencing. 11920956 Human
klk10 cancers CONCLUSIONS: We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. 11920956 Human
kallikrein 10 breast cancer Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance. 12087468 Human
kallikrein 10 breast cancer Both human kallikrein 6 and human kallikrein 10 are found to be down-regulated in breast cancer cell lines, suggesting that they may be involved in breast cancer pathogenesis and progression. 12087468 Human
kallikrein 10 breast cancer In this study, we investigated the potential value of human kallikrein 6 and human kallikrein 10 as prognostic and predictive factors in breast cancer. 12087468 Human
kallikrein 10 tumour We quantified human kallikrein 6 and human kallikrein 10 protein levels in 749 breast tumour cytosolic extracts and correlated this data with various clinicopathological variables and patient outcomes. 12087468 Human
kallikrein 10 tumours Higher human kallikrein 6 and human kallikrein 10 protein levels are associated with younger age, pre-menopausal, status and tumours which are negative for oestrogen and progesterone receptors. 12087468 Human
kallikrein 10 tumour No correlation was found between human kallikrein 6 and human kallikrein 10 levels and tumour size, grade, and nodal status. 12087468 Human
kallikrein 10 breast cancer Taken together, our results suggest that although human kallikrein 6 and human kallikrein 10 are not prognostic markers for breast cancer, human kallikrein 10 is an independent predictive marker for response of tamoxifen therapy. 12087468 Human
nes1 breast cancers It is now recognized that mutations in some tumor suppressor genes, such as p53, BRCA1, BRCA2, PTEN, or ATM, or epigenetic functional inactivation of other tumor suppressor genes, such as SYK and NES1, appear to play important early roles in the formation 12382187 Human
nes1 tumor It is now recognized that mutations in some tumor suppressor genes, such as p53, BRCA1, BRCA2, PTEN, or ATM, or epigenetic functional inactivation of other tumor suppressor genes, such as SYK and NES1, appear to play important early roles in the formation 12382187 Human
klk10 tumor KLK10 may act as a tumor suppressor. 12876620 Human
kallikrein 10 ovarian carcinoma Human kallikrein 10: a novel tumor marker for ovarian carcinoma? 11282101 Human
kallikrein 10 tumor Human kallikrein 10: a novel tumor marker for ovarian carcinoma? 11282101 Human
klk10 tumour Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. 11461080 Human
normal epithelial cell-specific 1 tumour Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. 11461080 Human
nes1 tumour Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue. 11461080 Human
nes1 tumour Experimental evidence suggests that NES1 controls normal cell growth and may function as a tumour suppressor. 11461080 Human
nes1 breast cancer NES1 is down-regulated during breast cancer progression. 11461080 Human
nes1 tumours In all 14 primary testicular germ-cell tumours examined, the NES1 gene expression was markedly reduced compared to adjacent (paired) normal tissues. 11461080 Human
nes1 carcinoma in situ (cis) We confirmed the differential expression of the NES1 gene in germ-cell tumours (GCT) and pre-malignant carcinoma in situ (CIS). 11461080 Human
nes1 tumours We confirmed the differential expression of the NES1 gene in germ-cell tumours (GCT) and pre-malignant carcinoma in situ (CIS). 11461080 Human
nes1 tumour Our findings suggest that NES1 may act as a tumour suppressor and may play a role in the pathogenesis and progression of this malignancy. 11461080 Human
kallikrein 10 epithelial ovarian carcinoma Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. 11489815 Human
normal epithelial cell-specific-1 breast cancer The normal epithelial cell-specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary epithelial cells, but its expression is dramatically decreased in breast cancer cell lines. 11691827 Human
nes1 tumor Using a luciferase reporter system, we demonstrate that most tumor cell lines are able to support full or partial transcription from the NES1 promoter, suggesting a role for promoter-independent cis-acting mechanisms of loss of NES1 expression. 11691827 Human
nes1 breast cancer Using methylation-specific PCR and sequence analysis of sodium bisulfite-treated genomic DNA, we demonstrate a strong correlation between exon 3 hypermethylation and loss of NES1 mRNA expression in a panel of breast cancer cell lines and in primary tumors 11691827 Human
nes1 breast cancer Our results also suggest that hypermethylation of the NES1 gene may serve as a potential marker for breast cancer. 11691827 Human
nes1 prostate cancer PURPOSE: Normal epithelial cell specific-1 (NES1)/kallikrein 10 gene is expressed in normal mammary and prostate epithelial cells, but the expression of NES1 mRNA and protein is markedly reduced in established breast and prostate cancer cell lines althoug 11705853 Human
nes1 primary breast cancers Here, we wished to assess whether NES1 expression is down-regulated in primary breast cancers. 11705853 Human
nes1 ductal carcinoma in situ EXPERIMENTAL DESIGN: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating duct 11705853 Human
nes1 atypical ductal hyperplasia EXPERIMENTAL DESIGN: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating duct 11705853 Human
nes1 infiltrating ductal carcinoma EXPERIMENTAL DESIGN: We developed and used an in situ hybridization technique with an antisense NES1 probe to detect NES1 mRNA in sections of normal breast specimens, typical and atypical ductal hyperplasia, ductal carcinoma in situ, and infiltrating duct 11705853 Human
nes1 breast hyperplasia Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). 11705853 Human
nes1 ductal carcinoma in situ Significantly, 13 (46%) of 28 ductal carcinoma in situ specimens lacked NES1 expression, and the remaining 15 (54%) showed weak-to-moderate expression. 11705853 Human
nes1 infiltrating ductal carcinoma Finally, 29 of 30 (97%) infiltrating ductal carcinoma grades I-III samples lacked NES1 mRNA, with weak expression in the remaining one sample. 11705853 Human
nes1 tumor CONCLUSIONS: Our results demonstrate that NES1 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1 expression during tumor progression. 11705853 Human
nes1 breast cancer We suggest that NES1 expression may serve as a molecular tool in the study of breast cancer progression. 11705853 Human
nes1 other cancers Studies with larger series of specimens should help assess whether NES1 expression can be a diagnostic and/or prognostic marker in breast and other cancers. 11705853 Human
normal epithelial cell-specific 1 breast carcinoma The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. 10810385 Human
nes1 breast carcinoma The normal epithelial cell-specific 1 (NES1) gene is up-regulated by steroid hormones in the breast carcinoma cell line BT-474. 10810385 Human
normal epithelial cell-specific 1 breast cancer The normal epithelial cell-specific 1 (NES1) gene encodes a serine protease which was found to be down-regulated in breast cancer. 10810385 Human
nes1 breast cancer The normal epithelial cell-specific 1 (NES1) gene encodes a serine protease which was found to be down-regulated in breast cancer. 10810385 Human
nes1 breast cancer There is evidence that NES1 acts as a tumor suppressor gene in breast cancer cells. 10810385 Human
nes1 tumor There is evidence that NES1 acts as a tumor suppressor gene in breast cancer cells. 10810385 Human
nes1 breast cancer To further understand its role in breast tumorigenesis, we investigated the effect of estrogens, androgens, and progestins on NES1 gene expression, in the breast cancer cell line BT-474, at the transcription level. 10810385 Human
nes1 breast cancer These results suggest that the NES1 gene is primarily regulated by estrogen, but also by androgen and progestin in the breast cancer cell line BT-474. 10810385 Human
nes1 other cancers Many of the newly identified kallikrein-like genes are regulated by steroid hormones, and a few kallikreins (NES1, protease M, PSA) are known to be downregulated in breast and possibly other cancers. 10675891 Human
nes1 breast cancer NES1 appears to be a novel breast cancer tumor suppressor protein and PSA a potent inhibitor of angiogenesis. 10675891 Human
nes1 tumor NES1 appears to be a novel breast cancer tumor suppressor protein and PSA a potent inhibitor of angiogenesis. 10675891 Human
normal epithelial cell-specific 1 tumor The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. 14628074 Human
nes1 tumor The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. 14628074 Human
normal epithelial cell-specific 1 acute lymphoblastic leukemia The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. 14628074 Human
nes1 acute lymphoblastic leukemia The normal epithelial cell-specific 1 (NES1) gene, a candidate tumor suppressor gene on chromosome 19q13.3-4, is downregulated by hypermethylation in acute lymphoblastic leukemia. 14628074 Human
nes-1 tumor They included c-JUN, JUNB, JUND, FREAC-1/FoxF1, ZNF-44/KOX7, plectin, filamin, keratin-13, G(0)S2, and the putative tumor suppressors NES-1 and protease M. 14633706 Human
klk10 cancer Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. 14568187 Human
kallikrein 10 cancer Steroid hormone regulation of the human kallikrein 10 (KLK10) gene in cancer cell lines and functional characterization of the KLK10 gene promoter. 14568187 Human
klk10 cancer METHODS: To determine the role of steroid hormones in KLK10 gene expression, we investigated its modulation by 17beta-estradiol, 5alpha-dihydrotestosterone, norgestrel, dexamethasone and aldosterone, at both the transcription and translation level, in a p 14568187 Human
klk10 breast cancer RESULTS: The KLK10 expression was mainly up-regulated by estrogens, androgens and progestins, and to a lesser extent by dexamethasone and aldosterone in the breast cancer cell lines BT-474, MCF-7 and T-47D, both at the mRNA and protein levels. 14568187 Human
nes1 breast cancer The normal epithelial cell-specific 1 (NES1) gene is a recently identified novel serine protease-like gene which is down-regulated during breast cancer progression. 9647736 Human
normal epithelial cell-specific 1 breast cancer The normal epithelial cell-specific 1 (NES1) gene is a recently identified novel serine protease-like gene which is down-regulated during breast cancer progression. 9647736 Human
nes1 tumor The role for NES1 serine protease as a novel tumor suppressor. 9809976 Human
nes1 cancer Previously (Liu et al, Cancer Res., 56: 3371-3379, 1996), we isolated a novel serine protease-like gene--Normal Epithelial Cell Specific-1 (NES1)--that is expressed in normal mammary epithelial cells but is down-regulated in most breast cancer cell lines. 9809976 Human
nes1 breast cancer Previously (Liu et al, Cancer Res., 56: 3371-3379, 1996), we isolated a novel serine protease-like gene--Normal Epithelial Cell Specific-1 (NES1)--that is expressed in normal mammary epithelial cells but is down-regulated in most breast cancer cell lines. 9809976 Human
nes1 breast cancer Here, we demonstrate that stable expression of NES1 in the NES1-negative MDA-MB-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-independent growth and tumor formation in nude mice. 9809976 Human
nes1 tumor Here, we demonstrate that stable expression of NES1 in the NES1-negative MDA-MB-231 breast cancer cell line suppressed the oncogenicity as revealed by inhibition of the anchorage-independent growth and tumor formation in nude mice. 9809976 Human
nes1 cancers Fluorescence in situ hybridization localized the NES1 gene to chromosome 19q13.3, a region that contains genes for related proteases (including the prostate-specific antigen) and is rearranged in human cancers. 9809976 Human
nes1 prostate cancer Similar to breast cancer cell lines, prostate cancer cell lines also lacked NES1 mRNA and protein expression. 9809976 Human
nes1 breast cancer Similar to breast cancer cell lines, prostate cancer cell lines also lacked NES1 mRNA and protein expression. 9809976 Human
nes1 prostate cancer Together, these results strongly suggest a tumor-suppressor role for NES1 in breast and prostate cancer. 9809976 Human
nes1 human breast cancer Although expression of the NES1 mRNA was observed in all normal and immortalized nontumorigenic MECs, the majority of human breast cancer cell lines showed a drastic reduction or a complete lack of its expression. 8764136 Human
kallikrein 10 ovarian cancer The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. 12591730 Human
klk10 breast cancer Several lines of evidence suggest that members of the kallikrein family are involved in various malignancies such as prostate (PSA, KLK2, KLK15), ovarian (KLK4, KLK5, KLK6, KLK8, KLK10), and breast cancer (KLK10, KLK13, KLK14). 12633763 Human
klk10 ovarian cancer We found that seven KLK genes (KLK5, KLK6, KLK7, KLK8, KLK10, KLK11, and KLK14) are up-regulated in ovarian cancer. 12727843 Human
klk10 ovarian cancer Probing 2 normal and 10 ovarian cancer serial analysis of gene expression libraries with gene-specific tags for each KLK indicated that whereas no expression was detected in any normal libraries (with the exception of KLK10 and KLK11), these KLKs were fou 12727843 Human
klk10 testicular germ-cell tumors In testicular germ cell tumors, some tissue kallikrein genes, including KLK5, KLK10, KLK13 and KLK14, were found to be significantly down-regulated. 12752266 Human
klk10 testicular cancer In this paper, the expression of KLK5, KLK10, KLK13 and KLK14 in testicular cancer and their possible roles during testicular cancer development, as well as their clinical applications are briefly reviewed. 12752266 Human
nes1 invasive carcinoma Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. 12788170 Human
nes1 ductal carcinoma in situ Loss of expression of the putative tumor suppressor NES1 gene in biopsy-proven ductal carcinoma in situ predicts for invasive carcinoma at definitive surgery. 12788170 Human
nes1 invasive cancer NES1 is expressed in normal breast tissue and ductal hyperplasia but is absent or markedly diminished in invasive cancer. 12788170 Human
nes1 hyperplasia NES1 is expressed in normal breast tissue and ductal hyperplasia but is absent or markedly diminished in invasive cancer. 12788170 Human
nes1 ductal carcinoma in situ (dcis) In cases of ductal carcinoma in situ (DCIS), NES1 expression has been shown previously to be present in approximately 50% of specimens. 12788170 Human
nes1 low-grade dcis RESULTS: The initial diagnostic biopsy specimens showed that 17 of 17 high-grade, 3 of 7 intermediate-grade, and 3 of 5 low-grade DCIS specimens were negative for NES1 expression. 12788170 Human
nes1 invasive carcinoma Of the 6 cases of DCIS found to be positive for NES1 expression, none (0%) were subsequently found to have invasive carcinoma at definitive surgery. 12788170 Human
nes1 invasive carcinoma In contrast, the loss of NES1 expression in the initial diagnostic biopsy was associated with a 40% incidence of invasive carcinoma at definitive surgery. 12788170 Human
nes1 invasive cancer CONCLUSION: These results show that a lack of NES1 expression in DCIS identified at the diagnostic biopsy predicts for a high risk of invasive cancer in the definitive surgical specimen. 12788170 Human
nes1 intermediate-grade dcis The predictive value of NES1 expression appears to be particularly relevant for low- and intermediate-grade DCIS. 12788170 Human
kallikrein 10 epithelial ovarian carcinomas Overexpression of kallikrein 10 in epithelial ovarian carcinomas. 12821340 Human
klk10 ovarian carcinoma We investigated whether KLK10 and its related protein, hK10, might serve as equally accurate markers for ovarian carcinoma. 12821340 Human
klk10 ovarian carcinoma Thirty-two of 35 primary serous ovarian carcinoma samples (91.4%) expressed higher levels of KLK10 than NOE did. 12821340 Human
klk10 epithelial ovarian carcinoma Eleven of 15 nonserous epithelial ovarian carcinoma samples (73.3%) and 8 of 11 primary peritoneal carcinoma samples (72.7%) also expressed KLK10. 12821340 Human
klk10 primary peritoneal carcinoma Eleven of 15 nonserous epithelial ovarian carcinoma samples (73.3%) and 8 of 11 primary peritoneal carcinoma samples (72.7%) also expressed KLK10. 12821340 Human
klk10 carcinoma tumor Overall, 84.8% of all epithelial ovarian and peritoneal carcinoma tumor samples showed elevated expression of KLK10. 12821340 Human
klk10 tumor Finally, in situ hybridization established that KLK10 mRNA is much more highly expressed by tumor tissue than by normal epithelium and stromal tissues. 12821340 Human
klk10 ovarian carcinoma Thus, it is likely that KLK10 and other kallikreins will serve as useful diagnostic and prognostic markers in patients with ovarian carcinoma. 12821340 Human
nes1 intermediate-grade dcis Additional stratification by nuclear grade showed invasive carcinoma in 5 (83%) of 6 NES1-negative, low- to intermediate-grade DCIS (p 12788170 Human
kallikrein 10 breast tumour We quantified human kallikrein 6 and human kallikrein 10 protein levels in 749 breast tumour cytosolic extracts and correlated this data with various clinicopathological variables and patient outcomes. 12087468 Human
kallikrein 10 tumor In addition, a panel of 11 genes known to encode potential tumor markers [mucin 1, transmembrane (MUC1), mucin 16 (CA125), mesothelin, WAP four-disulfide core domain 2 (HE4), kallikrein 6, kallikrein 10, matrix metalloproteinase 2, prostasin, osteopontin, 15161682 Human
kallikrein 10 cancer Identification of new splice variants and differential expression of the human kallikrein 10 gene, a candidate cancer biomarker. 16103744 Human
klk10 cancers of the prostate CONCLUSIONS: We found no evidence for somatic mutations of the KLK10 gene in cancers of the prostate, breast, ovary, and testis. 11920956 Human
klk10 testicular germ cell tumors In testicular germ cell tumors, some tissue kallikrein genes, including KLK5, KLK10, KLK13 and KLK14, were found to be significantly down-regulated. 12752266 Human
klk10 ovarian tumors RESULTS: KLK10 was more highly expressed by primary ovarian tumors than by NOE. 12821340 Human
klk10 malignancy KLK10 is highly expressed in the sex organs and its expression level changes in malignancy. 14568187 Human
klk10 cancer Experimental verification of differential expression of KLK10 in cancer was performed by PCR using gene-specific primers. 16103744 Human
klk10 gastric cancers SAGE analysis shows a clear upregulation of KLK10 in ovarian, pancreatic, colon, and gastric cancers. 16103744 Human
klk10 prostate cancers The differential regulation of KLK10 in ovarian and prostate cancers was experimentally verified by RT-PCR analysis. 16103744 Human
nes1 testicular germ-cell tumours In all 14 primary testicular germ-cell tumours examined, the NES1 gene expression was markedly reduced compared to adjacent (paired) normal tissues. 11461080 Human
nes1 germ-cell tumours We confirmed the differential expression of the NES1 gene in germ-cell tumours (GCT) and pre-malignant carcinoma in situ (CIS). 11461080 Human
nes1 malignancy Our findings suggest that NES1 may act as a tumour suppressor and may play a role in the pathogenesis and progression of this malignancy. 11461080 Human
nes1 primary tumors Using methylation-specific PCR and sequence analysis of sodium bisulfite-treated genomic DNA, we demonstrate a strong correlation between exon 3 hypermethylation and loss of NES1 mRNA expression in a panel of breast cancer cell lines and in primary tumors 11691827 Human
nes1 atypical breast hyperplasia Notably, 18 (75%) of 24 typical and atypical breast hyperplasia specimens showed high NES1 expression, with weak-to-moderate expression in 6 (25%). 11705853 Human
nes1 other tumor It is now recognized that mutations in some tumor suppressor genes, such as p53, BRCA1, BRCA2, PTEN, or ATM, or epigenetic functional inactivation of other tumor suppressor genes, such as SYK and NES1, appear to play important early roles in the formation 12382187 Human
nes1 ductal hyperplasia NES1 is expressed in normal breast tissue and ductal hyperplasia but is absent or markedly diminished in invasive cancer. 12788170 Human
nes1 dcis This study examined the expression level of NES1 in diagnostic biopsy samples found to contain pure DCIS. 12788170 Human
nes1 dcis Of the 6 cases of DCIS found to be positive for NES1 expression, none (0%) were subsequently found to have invasive carcinoma at definitive surgery. 12788170 Human
nes1 dcis CONCLUSION: These results show that a lack of NES1 expression in DCIS identified at the diagnostic biopsy predicts for a high risk of invasive cancer in the definitive surgical specimen. 12788170 Human
kallikrein 10 ovarian carcinomas The serum levels of four of these proteins (matrix metalloproteinase-7, osteopontin, secretory leukoprotease inhibitor, and kallikrein 10) were significantly elevated in a series of 67 independent patients with serous ovarian carcinomas compared with 67 h 17255266 Human
klk10 gastrointestinal cancers BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
klk10 tumors BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
klk10 colorectal cancer (crc) The aims of this study were to demonstrate expression and single nucleotide polymorphisms of KLK10 in colorectal cancer (CRC) and gastric cancer (GC), and to correlate the relative KLK10 expression level with clinicopathological factors of CRC and GC. 16928223 Human
klk10 gastric cancer (gc) The aims of this study were to demonstrate expression and single nucleotide polymorphisms of KLK10 in colorectal cancer (CRC) and gastric cancer (GC), and to correlate the relative KLK10 expression level with clinicopathological factors of CRC and GC. 16928223 Human
klk10 tumor Using quantitative real-time (qRT) RT-PCR and Western blot, KLK10 expression in tumor and non-tumor colorectal and gastric tissues was determined at the mRNA and protein levels. 16928223 Human
klk10 tumor KLK10 expression was much higher in tumor tissue than in the corresponding normal mucosal tissue at the mRNA and protein levels (P<0.01). 16928223 Human
klk10 gastric cancer The KLK10 mRNA expression level significantly correlated with the depth of GC invasion (P=0.018), clinical stage (P=0.045), patient sex (P=0.027) and Lauren type of gastric cancer (P=0.028). 16928223 Human
kallikrein 10 colorectal cancer Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. 16928223 Human
kallikrein 10 gastric cancer Clinical significance of human kallikrein 10 gene expression in colorectal cancer and gastric cancer. 16928223 Human
kallikrein 10 gastrointestinal cancers BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
kallikrein 10 tumors BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
nes-1 all To determine the extent of hypermethylation in ALL, we analyzed the methylation status of the CDH1, p73, p16, p15, p57, NES-1, DKK-3, CDH13, p14, TMS-1, APAF-1, DAPK, PARKIN, LATS-1, and PTEN genes in 251 consecutive ALL patients. 15198948 Human
nes-1 t-all PATIENTS AND METHODS: Methylation-specific polymerase chain reaction was used to analyze methylation of the ADAMTS-1, ADAMTS-5, APAF-1, ASPP-1, CDH1, CDH13, DAPK, DIABLO, DKK-3, LATS-1, LATS-2, NES-1, p14, p15, p16, p57, p73, PARK-2, PTEN, sFRP1/2/4/5, SH 16192589 Human
klk10 prostate cancers Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. 16254462 Human
klk10 breast cancer Recently, it has been shown that CpG island hypermethylation of the KLK10 gene is responsible for the tumor-specific loss of KLK10 gene expression in certain breast cancer cell lines. 16254462 Human
klk10 prostate cancers METHOD: We examined the role of CpG island hypermethylation in the tumor-specific loss of KLK10 expression in breast, ovarian and prostate cancers. 16254462 Human
klk10 prostate tumor RESULTS: Upregulation of KLK10 mRNA levels, which was accompanied by an increase in secreted hK10 protein concentration, was observed for a subset of breast, ovarian, and prostate tumor cell lines after 5-aza-2'-dC. 16254462 Human
klk10 tumors Screening against a series of established normal and malignant cell lines followed by screening against a panel of normal human tissues led to the identification of 7 genes (AREG, CDH3, KLK10, NmU, SLPI, ANAX3 and MAL2), which were over-expressed at least 16321566 Human
klk10 supraglottic laryngeal cancer Expression of AREG, CDH3, KLK10, NmU and SLPI at the protein level was determined by immunohistochemistry in seven supraglottic laryngeal cancer specimens. 16321566 Human
klk10 ovarian cancer Kallikreins 6 (KLK6) and 10 (KLK10) are elevated in tumour cells, serum and ascites fluid of ovarian cancer patients and correlate with disease prognosis. 16557045 Human
klk10 tumour Kallikreins 6 (KLK6) and 10 (KLK10) are elevated in tumour cells, serum and ascites fluid of ovarian cancer patients and correlate with disease prognosis. 16557045 Human
klk10 ovarian cancer We hypothesized that KLK6 and KLK10 can be utilized to monitor dissemination of ovarian cancer cells in blood and ascites fluid of ovarian cancer patients. 16557045 Human
klk10 other cancer Screening of ascites fluid of ovarian cancer patients revealed 90% positivity for KLK6 and KLK10 mRNA compared with 33% for other cancer types. 16557045 Human
klk10 ovarian cancer Screening of ascites fluid of ovarian cancer patients revealed 90% positivity for KLK6 and KLK10 mRNA compared with 33% for other cancer types. 16557045 Human
klk10 tumor For KLK10 and IGSF4, TIMP3 and FHIT, and TP73, in UMSCC-11B, UMSCC-17B, and UMSCC-81B, respectively, promoter hypermethylation was a disease progression event, indicating complete abrogation of tumor suppressor function for KLK10, IGSF4, and TIMP3 and gen 16785414 Human
klk10 non-small-cell lung cancer Quantitative analysis of KLK10 and KLK11 expression levels was assessed by real-time PCR, in a cohort of 47 patients with non-small-cell lung cancer (NSCLC). 16800740 Human
klk10 nsclc Quantitative analysis of KLK10 and KLK11 expression levels was assessed by real-time PCR, in a cohort of 47 patients with non-small-cell lung cancer (NSCLC). 16800740 Human
klk10 squamous cell carcinoma Multivariate analysis revealed a correlation between KLK10 over-expression and the squamous cell carcinoma histotype (p=0.034). 16800740 Human
klk10 nsclc These results suggest a co-regulation of KLK10 and KLK11 expression in lung and a lack of KLK10 suppressor role in NSCLC. 16800740 Human
kallikrein 10 ovarian cancers In ovarian cancers that lacked CA125, all specimens (100%) expressed human kallikrein 10 (HK10), human kallikrein 6 (HK6), osteopontin (OPN), and claudin 3. 16061277 Human
kallikrein 10 prostate cancers Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. 16254462 Human
kallikrein 10 cancer OBJECTIVE: The human kallikrein 10 (KLK10)/normal epithelial cell-specific-1 (NES1) gene is highly expressed in normal mammary, ovary and prostate cells, but its expression is dramatically decreased in cancer cell lines. 16254462 Human
kallikrein 10 human tumors OBJECTIVE: Kallikrein 10 is a secreted serine protease recently implicated in the growth and invasion of several human tumors. 16647913 Human
kallikrein 10 endometrial tumor The goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor. 16647913 Human
kallikrein 10 uterine serous papillary carcinoma The goal of this study was to investigate the expression and secretion levels in vitro and in vivo of kallikrein 10 in uterine serous papillary carcinoma, a highly aggressive variant of endometrial tumor. 16647913 Human
kallikrein 10 uterine serous papillary carcinoma STUDY DESIGN: Human kallikrein 10 gene expression levels were evaluated in 11 snap-frozen uterine serous papillary carcinoma biopsies and 6 normal endometrial cell biopsies by real-time polymerase chain reaction. 16647913 Human
kallikrein 10 endometrioid carcinomas Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA. 16647913 Human
kallikrein 10 papillary tumors Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA. 16647913 Human
kallikrein 10 endometrioid carcinomas Finally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied. 16647913 Human
kallikrein 10 uterine serous papillary carcinoma Finally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied. 16647913 Human
kallikrein 10 endometrioid carcinoma RESULTS: Kallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous pap 16647913 Human
kallikrein 10 uterine serous papillary carcinoma RESULTS: Kallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous pap 16647913 Human
kallikrein 10 papillary tumor In vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cul 16647913 Human
kallikrein 10 uterine serous papillary carcinoma In vitro kallikrein 10 secretion was detected in all primary uterine serous papillary carcinoma cell lines tested (mean = 2.7 microg/L), and the secretion levels were not significantly different to those found in primary ovarian serous papillary tumor cul 16647913 Human
kallikrein 10 endometrioid carcinomas In contrast, no kallikrein 10 secretion was detectable in primary endometrioid carcinomas. 16647913 Human
kallikrein 10 endometrioid carcinomas Kallikrein 10 serum and plasma concentrations (microg/L; mean +/- SEM) among normal healthy females (0.6 +/- 0.04), patients with benign diseases (0.6 +/- 0.06), and patients with endometrioid carcinomas (0.7 +/- 0.06) were not significantly different. 16647913 Human
kallikrein 10 endometrioid carcinoma In contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005 16647913 Human
kallikrein 10 uterine serous papillary carcinoma In contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005 16647913 Human
kallikrein 10 uterine serous papillary carcinoma CONCLUSION: Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients. 16647913 Human
kallikrein 10 uterine serous papillary carcinoma Kallikrein 10 may represent a novel biomarker for uterine serous papillary carcinoma. 16647913 Human
kallikrein 10 tumors The growth factor homologue Nel-like 2, dual specificity phosphatase 5, the serine protease kallikrein 10, and also the tight junction genes claudin 1 and claudin 16, were upregulated in classic PTC but not in aggressive tumors, which may be consistent wi 16676402 Human
kallikrein 10 colorectal cancer (crc) [Expression and single nucleotide polymorphisms of kallikrein 10 in colorectal cancer] OBJECTIVE: To demonstrate expression and single nucleotide polymorphisms (SNP) of human kallikrein 10 (KLK 10) in colorectal cancer (CRC) and to correlate the KLK 10 ex 16784657 Human
kallikrein 10 breast cancer Human kallikrein 10, a predictive marker for breast cancer. 16800732 Human
kallikrein 10 invasive breast cancers Human kallikrein 10 (hK10) protein is expressed in normal breast but is significantly downregulated in a majority of invasive breast cancers. 16800735 Human
nes1 prostate cancers Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers. 16254462 Human
nes1 cancer OBJECTIVE: The human kallikrein 10 (KLK10)/normal epithelial cell-specific-1 (NES1) gene is highly expressed in normal mammary, ovary and prostate cells, but its expression is dramatically decreased in cancer cell lines. 16254462 Human
klk 10 colorectal cancer (crc) [Expression and single nucleotide polymorphisms of kallikrein 10 in colorectal cancer] OBJECTIVE: To demonstrate expression and single nucleotide polymorphisms (SNP) of human kallikrein 10 (KLK 10) in colorectal cancer (CRC) and to correlate the KLK 10 ex 16784657 Human
klk 10 tumor The KLK 10 expression was much higher in tumor tissue than in the corresponding normal mucosal tissue at the mRNA and protein levels. 16784657 Human
kallikrein 10 uterine serous papillary carcinomas Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas. 16647913 Human
kallikrein 10 uterine serous papillary carcinomas Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA. 16647913 Human
nes1 tumorigenesis The structural similarity of NES1 to polypeptides known to regulate growth factor activity and a negative correlation of NES1 expression with breast oncogenesis suggest a direct or indirect role for this novel protease-like gene product in the suppression 8764136 Human
nes1 tumor Together, these results strongly suggest a tumor-suppressor role for NES1 in breast and prostate cancer. 9809976 Human
klk10 endocrine tumors BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
kallikrein 10 breast tumor CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. 11691827 Human
kallikrein 10 oncogenes Many of the genes upregulated in USPC were found to represent adhesion molecules, secreted proteins and oncogenes, such as L1 cell adhesion molecule, claudin-3 and claudin-4, kallikrein 6 (protease M) and kallikrein 10 (NES1), interleukin-6 and c-erbB2. 15785748 Human
kallikrein 10 primary tumor Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA. 16647913 Human
kallikrein 10 cancer In contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005 16647913 Human
kallikrein 10 ptc The growth factor homologue Nel-like 2, dual specificity phosphatase 5, the serine protease kallikrein 10, and also the tight junction genes claudin 1 and claudin 16, were upregulated in classic PTC but not in aggressive tumors, which may be consistent wi 16676402 Human
kallikrein 10 colorectal cancer [Expression and single nucleotide polymorphisms of kallikrein 10 in colorectal cancer] OBJECTIVE: To demonstrate expression and single nucleotide polymorphisms (SNP) of human kallikrein 10 (KLK 10) in colorectal cancer (CRC) and to correlate the KLK 10 ex 16784657 Human
kallikrein 10 endocrine tumors BACKGROUND AND AIM: Recent evidence suggests that the human kallikrein 10 (KLK10) gene is differentially regulated in endocrine-related tumors and has potential as diagnostic and/or prognostic marker; however, KLK10 expression has never been investigated 16928223 Human
nes1 tumorigenesis To further understand its role in breast tumorigenesis, we investigated the effect of estrogens, androgens, and progestins on NES1 gene expression, in the breast cancer cell line BT-474, at the transcription level. 10810385 Human
nes1 breast tumor CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. 11691827 Human
nes1 tumorigenesis PURPOSE: The loss of expression of NES1, a novel putative tumor suppressor gene, is an early marker of breast tumorigenesis. 12788170 Human
nes1 dcis Additional stratification by nuclear grade showed invasive carcinoma in 5 (83%) of 6 NES1-negative, low- to intermediate-grade DCIS (p 12788170 Human
nes1 invasive carcinoma Additional stratification by nuclear grade showed invasive carcinoma in 5 (83%) of 6 NES1-negative, low- to intermediate-grade DCIS (p 12788170 Human
nes1 oncogenes Many of the genes upregulated in USPC were found to represent adhesion molecules, secreted proteins and oncogenes, such as L1 cell adhesion molecule, claudin-3 and claudin-4, kallikrein 6 (protease M) and kallikrein 10 (NES1), interleukin-6 and c-erbB2. 15785748 Human
klk 10 colorectal cancer [Expression and single nucleotide polymorphisms of kallikrein 10 in colorectal cancer] OBJECTIVE: To demonstrate expression and single nucleotide polymorphisms (SNP) of human kallikrein 10 (KLK 10) in colorectal cancer (CRC) and to correlate the KLK 10 ex 16784657 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.